GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
GSK hails progress for withdrawn blood cancer drug
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Bloomberg L.P.1d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK Reports Positive Headline Results From DREAMM-7 Phase III Trial
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
GSK Vaccines’ shingles ad campaign warns about the year-round threat
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK Blenrep shows strong survival benefit in myeloma study
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
Hosted on MSN18h
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
FiercePharma1d
GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
MarketWatch16h
GSK falls Wednesday, underperforms market
GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...
Daily1h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
GSK’s Trelegy TV ad depicts the reality of living with COPD
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...